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The protective eﬀects of fruits, vegetables, and other foods on prostate cancer may be due to their antioxidant properties.
An imbalance in the oxidative stress/antioxidant status is observed in prostate cancer patients. Genome oxidative damage in
prostate cancer patients is associated with higher lipid peroxidation and lower antioxidant levels. Oxygen radicals are associated
with diﬀerent steps of carcinogenesis, including structural DNA damage, epigenetic changes, and protein and lipid alterations.
Epigenetics aﬀects genetic regulation, cellular diﬀerentiation, embryology, aging, cancer, and other diseases. DNA methylation is
perhaps the most extensively studied epigenetic modiﬁcation, which plays an important role in the regulation of gene expression
and chromatin architecture, in association with histone modiﬁcation and other chromatin-associated proteins. This review will
provide a broad overview of the interplay of oxidative stress and DNA methylation, DNA methylation changes in regulation of
gene expression, lifestyle changes for prostate cancer prevention, DNA methylation as biomarkers for prostate cancer, methods for
detection of methylation, and clinical application of DNA methylation inhibitors for epigenetic therapy.
1.Introduction
When diet is wrong medicine is of no use.
When diet is correct medicine is of no need.
Ayurvedic Proverb
[In Sanskrit, the word Ayurveda consists of the words Ayur,
meaning “life”, and veda, meaning related to knowledge’ or
“science”].
Prostate cancer is the most commonly diagnosed cancer
and a second leading cause of cancer death in men in
the United States, with the vast majority of the mortality
arising from the castration-resistant and/or metastatic forms
of the disease [1]. Obesity and inadequate eating habits may
promote prostate cancer development [2]. A healthy weight
and a diet low in total fat, saturated, monounsaturated,
and polyunsaturated fat and rich in omega-3 fatty acids,
vitamin C, vitamin E, lycopene, alpha-tocopherol, selenium,
beta carotene, and quercetin are inversely associated with
prostate cancer risk [3, 4]. The beneﬁcial eﬀects of these
nutrients in prevention of prostate cancer may be related
to antioxidant levels. Among chemicals present in food,
curcumin, Epigallocatechin-3-gallate (EGCG) and genistein
have demethylation activity [5–7]. Epidemiological studies
have indicated a link between a low occurrence of prostate
cancer and diets rich in these compounds [7–9].
“Oxidative stress” is the state of a cell, which is char-
acterized by excess production of reactive oxygen species
(ROS) and/or a reduction in antioxidant defenses respon-
sible for metabolism. ROS are formed as a natural by-
product of the normal metabolism of oxygen. Under normal
circumstances, the cell is able to maintain an adequate
homeostasis between the formation of ROS and its removal
through enzymatic pathways or via antioxidants [10]. If,
however, this balance is disturbed, then oxidative stress
occurs. This generates an imbalance of production/removal
of ROS, which is either directly or indirectly involved in
initiation,promotion,andprogressionphasesofcarcinogen-
esis [11]. Oxygen radicals may cause damage to DNA and
chromosomes, induce epigenetic alterations, interact with
oncogenes or tumor suppressor genes, and impart changes
in immunological mechanisms [12, 13]. The extent of ROS-
induced oxidative damage can be exacerbated by a decreased
eﬃciency of antioxidant defense mechanisms. Endogenous2 Obstetrics and Gynecology International
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Figure 1: Eﬀect of oxidative stress on DNA methylation. Antioxidant enzymes, for example, GSTP1 or antioxidants scavenge the ROS in
normal cells. (A)depicts hypomethylation of DNA by ROS. , ,a n d represent DNA base modiﬁcation, DNA deletion, and chromosomal
breakage,respectively,allofwhichinterfereDNMTactivity.(B)UnderincreasedROSconcentrations;theMBPs,HDACandDNMTcomplex
methylate the CpG sites resulting in reduced GSTP1 expression. Further increase in ROS results in complete loss of GSTP1 ( )b y
hypermethylation. (C) and (D) represent ROS-mediated oxidation of guanine to 8-Oxy guanine and cytosine to hydroxymethyl cytosine,
respectively. Both modiﬁcations interfere with MBP-mediated methylation (details are given in the text).
defenses against ROS include antioxidant enzymes such as
glutathione-s-transferase P1 (GSTP1), glutathione peroxi-
dase, catalase, and superoxide dismutase [14]. Many factors
such as diet, environmental carcinogens, aging, and other
inﬂammatory diseases associated with aberrant changes in
ROS may play important roles in the development and
progression of prostate cancer [15–17]. Regulating such
factorsmayoﬀeraneﬀectivemeansforpreventingortreating
prostate cancer.
2. OxidativeStressand DNA Methylation
Oxidative stress either by metabolic, dietary, environmental,
or other means leads to increased production of ROS.
Generation of the hydroxyl radical can cause a wide range of
DNA lesions including base modiﬁcations, deletions, strand
breakage, and chromosomal rearrangements [18, 19]. Such
DNA lesions have been shown to interfere with the ability
of DNA to function as a substrate for the DNA methyl
transferases (DNMTs), resulting in global hypomethylation
(Figure 1(A)) [20]. ROS production is associated with
increased DNA damage and chromosomal degradation with
alterations of both hypermethylation and hypomethylation
oftheDNA[21].ChronicincreaseofROSinthecellscanalso
result in lipid peroxidation and generation of a wide range of
other reactive products with the potential to damage DNA
[22]. Antioxidant enzymes and/or antioxidants scavenge the
ROS produced in the cells. An increased vulnerability to
genome-damaging stresses from electrophiles and oxidants,
attributable to lack of GSTP1, may be the critical feature per-
mitting prostate carcinogenesis. Inactivation of GSTP1 may
leave cells vulnerable to oxidative damage and/or tolerant
to accumulation of oxidized DNA base adducts. Hyperme-
thylation of the GSTP1 promoter with reduced expression
levels is detected in precursor high-grade intraepithelial
neoplasia(HG-PIN)[23].AbsenceofGSTP1expressionwith
promoter hypermethylation is evident in prostate cancer
(Figure 1(B)) [24, 25]. In CpG dinucleotides, the cytosine is
thepreferredbaseforDNAmethylation,whereastheguanine
is the site for oxidative damage. The guanine oxidative
product, 8-oxoguanine (8-oxoG), is a major form of DNA
damage [26–28] .T h u s ,i ti sw i d e l yu s e da sab i o m a r k e ro f
oxidative damage [29]. The N7 position of guanine acts asObstetrics and Gynecology International 3
a hydrogen bond acceptor in the formation of the methyl
binding protein (MBP)-DNA complex. The oxidation of
guanine to 8-oxoG converts the N7 position of guanine from
a hydrogen bond acceptor into a hydrogen bond donor,
as well as replaces the 8-proton with an oxygen atom.
Replacement of guanine to 8-oxoG substantially diminishes
MBP binding when 8-oxoG is adjacent to the 5-methyl-
cytosine (Figure 1(C)) [30–33]. In addition, the methyl
group of 5-methyl-cytosine is susceptible to oxidation and
cangenerate5-hydroxymethylcytosine[34].Methylgroupof
5-methyl cytosine is important for sequence-speciﬁc DNA-
protein interactions [31, 35]. Replacement of 5-methyl-
cytosine to hydroxymethyl cytosine reverses the binding
aﬃnity to MBPs, interfering with subsequent steps in the
chromatin condensation cascade, resulting in potentially
heritable epigenetic alterations (Figure 1(D)).
3. Regulation of Gene Expressionby
DNA Methylation
In mammalian cells, most of the chromatin exists in a
condensed, transcriptionally silent form called heterochro-
matin. Euchromatin is less condensed, and contains most
of the actively transcribed genes. Histones and DNA are
chemically modiﬁed with epigenetic markers that inﬂuence
chromatin structure by altering the electrostatic nature of
the chromatin or by altering the aﬃnity of chromatin-
bindingproteins.DNAmethylationisusuallyassociatedwith
histone deacetylation, chromatin condensation, and gene
silencing [36–38]. DNA methylation leads to gene silencing
either by inhibiting the access of target binding sites to the
transcriptional activators [39] or by promoting the binding
of methyl-binding domain proteins, which can mediate
repression through interaction with histone deacetylases
(HDACs) [40, 41] that promote chromatin condensation
into transcriptionally repressive conformations.
DNA methylation involves the addition of a methyl
group to the ﬁfth carbon position of the cytosine pyrimidine
ring via a methyltransferase. This covalent modiﬁcation of
multiple sites on DNA by methylation is a heritable and
reversible epigenetic process, which is involved in regulation
of a diverse range of biological processes [42–44]. The de
novo methyltransferases DNMT3A and DNMT3B methylate
the genome during embryonic development, whereas the
maintenance DNA methyltransferase DNMT1 methylates
hemimethylated DNA following DNA replication. The pre-
ponderance of DNA methylation occurs at 5 ...CpG...3 
dinucleotides, but other methylation patterns do exist. In
fact, 80 percent of all 5 ...CpG...3  dinucleotides are
methylated, whereas the majority of the 20% that remain
nonmethylated are within promoters or in the ﬁrst exons
of genes [45]. CpG dinucleotides are relatively infrequent
in the human genome, except in CpG islands, which
are (0.2 to 2kb) regions highly enriched in CpGs [46].
Approximately 50% to 60% of gene promoters lie within
CpG islands. CpG methylation outside of CpG islands is
thought to suppress transcription of transposable elements
and spurious initiation of transcription elsewhere.
DNA methylation abnormalities, either gain of methyla-
tion in normally unmethylated promoters or other regula-
tory regions (hypermethylation), contribute to tumorigen-
esis by decreasing activity of tumor suppressor genes. Loss
of methylation in normally methylated repetitive sequences
(hypomethylation) that leads to activation of protoonco-
genes and genomic instability is evident in almost all human
tumor types [42, 47, 48]. DNA methylation is the best-
established epigenetic mark that is critical for the allele-
speciﬁc expression of imprinted genes [49]. Hypomethyla-
tion of speciﬁc chromosomal domains has been linked to
chromosomal instability [50]. Chromosomal abnormalities
associated with hypomethylation include isochromosomes,
unbalanced juxtacentromeric translocations, and whole-arm
deletions. DNA hypomethylation of repetitive elements,
retrotransposons, and CpG poor promoter regions plays an
important role in tumorigenesis [51]. Hypomethylation of
repetitive sequences and retrotransposons is associated with
chromosomal rearrangements and translocation to other
genomic regions, thereby promoting genomic instability [44,
52, 53].
4. LifestyleChanges andProstateCancer
The doctor of the future will give no medication, but will
interest his patients in the care of the human frame, diet and
in the cause and prevention of disease. ∼Thomas Edison.
4.1.DietaryFactors. Epigeneticchangescanbemodulatedby
molecules that are part of our daily diet. Caloric restriction
is associated with myriad changes, including an increased life
span, at least in animal models, and potentially delays a wide
range of diseases including cancer [54]. Increasing evidence
from epidemiology and laboratory studies suggests that diet
and lifestyle may have a role in the development of prostate
cancer [55–57]. In a recent Prostate Cancer Lifestyle Trial
(PCLT) [58], 93 men with early prostate cancer (who had
optedforactivesurveillancebeforethestudy)wererandomly
assigned to either a 1-year intensive lifestyle change program
or to a usual care control group [55–60]. The intensive
lifestyle program included a vegan diet (supplemented
with soy, ﬁsh oil, vitamin E, selenium, and vitamin C),
moderate aerobic exercise (walking 30 minutes 6 days
weekly), stress management techniques (gentle yoga-based
stretching, breathing, meditation, imagery, and progressive
relaxation for a total of 60 minutes daily), and participation
in a 1-hour weekly support group to enhance adherence to
the intervention [57]. The diet was predominantly fruits,
vegetables, whole grains (complex carbohydrates), legumes,
and soy products, was low in simple carbohydrates, and
included approximately 10% of calories from fat [61]. This
study found that the patients in the experimental group
had a signiﬁcant reduction in PSA levels and had fewer
prostate cancer-related clinical events compared with the
controls at the end of the 1-year program. Also, after 1
year, the growth of prostate cancer cell line, LNCaP cells
was inhibited almost 8 times more by serum from the
experimental than from the control group (70% versus 9%)4 Obstetrics and Gynecology International
[55]. Furthermore, the experimental patients had greater
improvements in cardiovascular health parameters than did
control patients, as shown by lowered total and low-density
lipoprotein and cholesterol levels, which might translate into
a reduction in cardiac events over the long term. This is
especially important because, in general, men with prostate
cancer are more likely to die of cardiovascular disease than of
prostate cancer [62] .T h ep r e v e n t i v ee ﬀects of this trial may
b ed u et ot h er e d u c t i o no fs t r e s sl e v e l sa n dt h ep r o t e c t i v e
eﬀects of antioxidants from the vegetables and fruits. Many
men are making changes in diet and lifestyle in the hope
of preventing or slowing the progression of prostate cancer
[57].
The anticancer properties attributed to several bioactive
food components, encompassing both essential nutrients
and nonessential components, may relate to DNA methy-
lation patterns [63]. Global DNA methylation alterations
in prostate cancer are correlated with adaptive changes
in several signaling pathways that may be inﬂuenced by
lifestyle changes. Dietary factors may inﬂuence the sup-
ply of methyl groups available for the formation of S-
adenosylmethionine (SAM), a coenzyme involved in methyl
group transfer. Moreover, dietary factors may modify the
utilization of methyl groups by processes including shifts
in DNMT1 activities. Finally, DNA methylation patterns
may inﬂuence the response to a bioactive food component.
Several lines of evidence suggest that DNA hypomethylation
and chromosome instability may result from insuﬃcient
dietary folate. Folate provides carbon units for a number
of biochemical processes, including production of SAM,
a universal methyl donor that also supplies the methyl
group on cytosines in DNA. The eﬀect of reduced dietary
folate on hypomethylation is observed in dietary studies in
humans, and the hypomethylation is reversible by controlled
folate repletion [64]. SAM is required for the biosynthesis
of the polyamines spermidine and spermine, which are
produced by normal prostate secretory cells. One of the
possibleexplanationsforalimitationinSAMistheincreased
requirement for folate biosynthesis in proliferating cancer
cells. Insuﬃcient concentrations of SAM for DNA methy-
lation in cancers may be caused by an insuﬃcient supply
of metabolic precursors, for example, methionine, folate,
vitamin B12, zinc and choline, or increased demands from
various other methylation reactions [65–67]. Methionine
deprivation stress induces apoptosis, which is mediated
by downregulation of TP53 and increased production of
TRAIL and proinﬂammatory cytokines [68]. Imbalances of
nutrients and other bioactive food components have been
shown to lead to global DNA hypomethylation, and gene-
speciﬁc hypomethylation and/or hypermethylation.
4.2. Risk Factors. A few well-established risk factors for
prostate cancer incidence include increasing age, race, eth-
nicity, and a positive family history. Higher ROS-mediated
oxidative stress was detected more in the epithelium of
prostate cancer patients than men without the disease [12].
The association of ROS with race remains to be elucidated.
Ar a c i a ld i ﬀerence in the methylation status of the GSTP1,
CD44, ESR, and CDH1 genes is associated with prostate
cancer. A 1.7-fold higher frequency of CD44 methylation
was observed among African Americans (43%) relative
to Caucasians (25%) [69]. Cigarette smoke is potentially
capable of generating a high load of free radicals in the
body. The eﬀect of dietary and environmental risk factors
on prostate cancer was evaluated in a recent NIH-AARP
Diet and Health study. The data conﬁrmed a number of
observational studies linking smoking to prostate cancer
mortality [70]. Interestingly, current (but not former) smok-
ers had a higher mortality from prostate cancer, suggesting
that smoking cessation could lead to improved survival.
A signiﬁcant correlation of methylation status of multiple
genes with smoking status in prostate cancer has been
observed [71]. Epigenetic alterations are also attractive
targets of environmental carcinogenesis. Nickel and arsenic
metals, butyrate: a short chain fatty acid, Phenobarbital:
the tumor promoting agent, nicotine-derived nitrosamine
ketone (NNK): a tobacco-speciﬁc carcinogen and methylene
chloride: an occupational carcinogen, methionine and cyti-
dine analogs are some of the agents known to alter cytosine
methylation patterns of the promoter tumor suppressor
genes and oncogenes [72–77].
4.3. Aging. The concept that environment might change your
hereditary without changing a gene sequence is the front lines
of Epigenetics. As life is changing all the time, the epigenetic
code that controls the DNA is turning out to be the mechanism
through which we change along with it.
Prostate cancer is mostly a disease of elderly men.
The progressive inherent or acquired changes in cellular
metabolism occurring with aging may play an important
role in the development of this disease. ROS generated either
endogenously (mitochondria, metabolic process, inﬂamma-
tion, etc.) or from external sources, due to decreases in
intracellular ROS scavenging system plays a vital role in
regulating several biological phenomena [78, 79]. There is
a growing evidence that the epigenetics of an individual
changes with aging, especially the accumulation of DNA
methylation and histone deacetylation [69, 80–82]. Aging of
the immune system, or immunosenescence, is characterized
by a decline of both T and B cell function, and paradoxically
the presence of low-grade inﬂammation. Androgen receptor
(AR) is up-regulated in an age-associated manner in man
and promotes continued proliferation and diﬀerentiation of
the prostate [83]. Normal androgen levels can promote the
production and accumulation of ROS in prostate cancer
cells. Androgen-induced increase in ROS levels in prostate
epithelial cells plays a key role in prostate cancer occurrence,
recurrence, and progression [84]. The involvement of oxida-
tive stress as an early event in prostate cancer development
was suggested by Miyake et al. [85] who showed that andro-
gen suppression is capable of decreasing oxidative stress.
In addition, overproduction of H2O2 plays a major role
in androgen-independent cell proliferation and migration
of LNCaP cells [86]. However, metastatic human prostate
cancers from anorchid men express transcripts encoding
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androgens at concentrations capable of activating AR target
genes and maintaining tumor cell survival [87].
Epigenetic mechanisms linking aging to cancer include
hypermethylation of the promoter of tumor suppressor
genes such as RB1, p16 and Wnt-associated factors, aberrant
DNMT activity, loss of genomic imprinting, and chromoso-
mal translocations in hypomethylated DNA sequences [88,
89]. Serum levels of Interleukin-6 (IL-6), which regulates
the promoter activity of DNMT1, increase with age [90].
Total genomic 5-methylcytosine decreases during aging and
is inversely proportional to the maximum life span potential
of an individual [91]. A longitudinal study of 718 elderly
individuals between 55 and 92 years of age demonstrated
that repetitive element methylation, particularly in ALU
sequences, decreases throughout aging [92]. It has been
postulated that the reduction of DNMT1 activity with age
contributes to the decrease in global DNA methylation
[93]. Telomerase activity is linked to multiple developmental
processes, including cell proliferation, diﬀerentiation, aging,
and senescence. Telomere length and rate of telomere
shorting are indicators of mitotic cell age, because telomers
shorten during normal cell divisions [94]. The aspect of
cellular aging that is conferred by diminished telomere
maintenance appears to be an important precursor to the
development of many types of cancer. Shortened telomers
predict poor clinical outcomes, including increased risk
of metastasis and prostate-cancer recurrence in patients
undergoing radical prostatectomy [95]. Comprehensive
lifestyle changes signiﬁcantly increase telomerase activity
and consequently increased telomere maintenance capacity
in human immune-system cells [96]. Recent studies have
shown that tumor telomere length and integrity can be
inﬂuenced by the epigenetic status of cancer cells [97].
Methylation status of subtelomeric DNA repeats negatively
correlates with telomere length and telomere recombination
in cancer cell lines. Treatment of human cancer cell lines
with demethylating drugs results in hypomethylation of
subtelomeric repeats and increased telomere recombination,
which in turn could facilitate telomere elongation [98].
5. DNA Methylation for Early Detection and
Predictionof Metastatic Risk
In recent years, there has been an enormous eﬀort to
develop speciﬁc and sensitive biomarkers for precise and
accurate screening, diagnosis, prognosis, and monitoring
of high risk cancer. The cancer epigenome is characterized
by global changes in DNA methylation and histone mod-
iﬁcation patterns as well as altered expression proﬁles of
chromatin modifying enzymes. Indeed, DNA methylation
changes appear to be more frequent events than genetic
mutations [99, 100]. If aberrant methylation of CpG sites
in noncancer tissues is associated with a risk for cancer
development, it may be used as a cancer risk marker.
Aberrant DNA methylation may be among the earliest
changes to occur during oncogenesis [101]. Once epigenetic
modiﬁcations are established in premalignant tissues, the
extent of modiﬁcations may accumulate as the disease
progresses [102–104]. Aberrant DNA methylation of CpG
sites in cancer cells may be used to detect cancer cells in
biopsy samples or cancer-derived DNA in plasma. When
imbalances in methylation contribute to tumor progression,
methylation changes should increase in frequency and/or
severity coordinately with increasing malignancy grades [24,
105]. If methylation of CpG sites is associated with a disease
phenotype, then it can be used as a marker to predict
phenotype, which may facilitate prognosis or prediction of
responses to therapy.
Evidence for DNA methylation as an early event comes
from studies of clinical samples, where DNA methylation
changes were detected in early preneoplastic lesions [106].
Of all the genes known to be methylated in prostate cancer,
GSTP1 is the most frequently methylated gene. GSTP1
is a detoxifying enzyme that helps to catalyze conjuga-
tion reactions between potentially damaging oxidants, elec-
trophiles, and glutathione [107, 108]. Expression of GSTP1
is diminished or absent in prostate cancer, and this absence
is tightly regulated by hypermethylation of the promoter
CpG Island [24]. Although hypermethylation of GSTP1
is rarely detected in normal prostate or benign prostatic
hyperplasia (BPH), it is hypermethylated in >90% of cancers
and about 70% of precursor high grade intraepithelial
neoplasia(PIN)lesions[109,110].Thus,GSTP1methylation
has improved the standard histological diagnosis in sextant
biopsies [111]. In addition, GSTP1 methylation is correlated
with Gleason grade and prostate cancer volume, suggesting
that quantitative GSTP1 methylation may be of prognostic
signiﬁcance [112]. GSTP1 methylation is evident in 90%
of lymph nodes from prostate cancer patients but in only
11.1% of lymph nodes from noncancer patients, suggesting
that detection of GSTP1 could have a role in molecular
staging of prostate cancer [113]. The inactivation of GSTP1
may leave cells vulnerable to oxidative DNA damage and/or
tolerant to accumulation of oxidized DNA base adducts.
Taken together, these results suggest that prostatic cells
in proliferative inﬂammatory atrophy lesions, which are
exposedtoinﬂammatoryoxidants,induceGSTP1expression
as a defense against oxidative genomic damage. Cells with
ad e f e c t i v eGSTP1 gene may become vulnerable to oxidants
and electrophiles that can inﬂict genomic damage, which in
turn may promote transformation of PIN to prostate cancer
[114].
Analysis of multiple gene methylation patterns, as com-
pared to that of a single gene, can improve the ability
to distinguish cancerous from benign prostate tissues, and
also improves correlations with pathological features such
as, stage, grade, and recurrence [115]. Hypermethylation
of multiple genes (including GSTP1, RAR-2β,a n dAPC)
identiﬁed prostate cancer in histopathologically negative
biopsy samples collected from men who were later positively
diagnosed during a follow-up biopsy procedure [116]. We
have shown that hypermethylation of RAR-2β, GSTP1,
PDLIM4, and FLNC facilitates the diagnosis of prostate
cancer with a sensitivity and speciﬁcity of 87.3% and
87.1%, respectively [24, 82, 117]. Methylation of the RAR-
2β promoter could discriminate between neoplastic and
nonneoplastic tissues with 94.9% sensitivity and 100%6 Obstetrics and Gynecology International
speciﬁcity [118]. Hypermethylation of a combination of
genes including APC, RASSF1A, PTGS2, PDLIM4, and
MDR1 could distinguish cancer from benign prostate tissues
with sensitivities of 97.3%–100% and speciﬁcities of 92%–
100% [24, 119]. The increase in methylation of these genes
with cancer progression indicates that they could be used
for biomarkers for both diagnosis and risk assessment
[120, 121]. Furthermore, we showed signiﬁcant diﬀerences
in the frequency of methylation at individual CpG sites
of PITX2, PDLIM4, KCNMA1, GSTP1, FLNC, EFS, and
ECRG4 in recurrent and nonrecurrent subtypes of prostate
tumors [24]. Indeed, hypermethylation of a CpG island
in PITX2 portended an increased risk of prostate cancer
recurrence [105] and was a predictor of distant disease
recurrenceintamoxifen-treated,node-negativebreastcancer
patients [122]. Moreover, speciﬁc CpG sites of FLNC and
EFS, genes involved in cell attachment, are associated with
systemic recurrence [24]. Remarkably, the combination of
methylationscorewithGPSMscoreimprovedthetheoretical
prediction of recurrence. A GPSM score is a prognostic
model using the weighted sum of the pathological Gleason
score, preoperative PSA, seminal vesicle involvement, and
marginal status to predict biochemical progression after
radical prostatectomy [82]. These data suggest that DNA
methylation analysis could augment the ability of currently
available predictors of prostate cancer progression.
CpG island methylation may precede genetic instability
in cancer cells. The MLH1 and 14-3-3 sigma genes, both
important for genome integrity, are frequently silenced
by aberrant methylation [123]. MLH1 encodes a DNA
mismatch repair protein. MLH1 promoter methylation and
gene silencing are signiﬁcantly correlated with microsatellite
instability [124, 125]. Experimental demethylation in tumor
cell lines results in reexpression of MLH1 and restoration of
a DNA mismatch repair proﬁcient phenotype [126]. Hyper-
methylation of hMLH1 and p14/INK4a CpG islands is rare
in primary cancers and more common in metastatic disease
[127,128].DNAmethylation-inducedsilencingofgenesmay
be involved in the regulation of the self-renewal capacity of
stem-precursor cells. For example, hypermethylation of p16
andAPC iscommonlyobservedintheearlystagesofprostate
cancer [129]. Also, other hypermethylated genes, including
CDH1, CDKN2A, CD44, CAV1, HOXD3, and BMP7, have
been demonstrated in prostate cancer [130–132]. Methyla-
tion of CDH1 and CD44 is increased in advanced prostate
tumors, suggesting that they might be useful markers to
assess tumor progression [131]. Comparison of methylation
patternsinlowandhigh-gradecancerssuggeststhatHOXD3,
BMP7, and EDNRB may play a role in the development
of high-grade tumors [133]. Hypermethylation of APC and
RUNX3 wasassociatedwithincreasedriskofprostatecancer-
speciﬁc mortality [134].
In contrast to hypermethylation, hypomethylation of
genomic 5meCytosine content in LINE1 elements and CpG
islands of gene promoters may lead to overexpression of
genes [135]. LINE1 elements are the largest class of repetitive
elements in the human genome. Hypomethylation of LINE1
elements can lead to transcriptional activation, induction
of retrotransposition, and facilitation of genetic instability
[136]. There appears to be a causal relationship between
hypomethylation and chromosomal instability [137]. DNA
hypomethylation occurs late in prostate cancer progression
and is likely to be involved in the formation and progression
of metastases [135]. DNA hypomethylation is a signiﬁcant
source of tumor heterogeneity in metastatic prostate cancer
and may contribute to the development of therapeutic
resistance [138, 139]. Gene-speciﬁc hypomethylation can
cause heterogeneous overexpression of a series of cancer-
testisantigengenes(CTA),manyofwhicharecurrentlybeing
evaluated as targets of immunotherapy. Clinical trials have
shown regression of tumors when patients are treated with
immunotherapies targeted to these CTA antigens [140, 141].
Noninvasive and minimally invasive tests, particularly
those that provide molecular signatures in blood samples,
may enhance our ability to detect prostate cancer [142, 143].
Cell-free circulating DNA in blood plasma exhibits cancer-
associated changes in DNA methylation, and thus represents
an attractive biomarker assay. Hypermethylation of GSTP1
was found in 94% of tumors, 72% of plasma or serum
samples, 50% of ejaculate, and 36% of urine from patients
with prostate cancer [144, 145]. Hypermethylation of GSTP1
CpG island sequences could be detected in prostatic secre-
tions collected from 96% of radical prostatectomy specimens
[146]. The abnormal DNA methylation patterns in these
secretions may have come from prostate cancer cells, or from
PIN cells shed into prostate ducts. Methylated DNA in blood
and urine may serve as a screen for prostate cancer and may
identifymenatriskfordevelopingaggressivedisease.Indeed,
a dual-assay based on both genetic and epigenetic alterations
in multiple microsatellite and methylation markers in circu-
lating DNA from serum samples exhibited greater sensitivity
for prostate cancer detection than that of a single-marker
assay and was independent of PSA levels or the American
Joint Cancer Committee (AJCC) stage [147]. Prognostic
markers may help to identify those patients who will recur
with cancer. Furthermore, accurate risk prediction may help
identify patients who would beneﬁt from more aggressive
treatments immediately following primary therapy or select
patients for active surveillance.
6. Methods for Detection of DNA Methylation
Epigenome mapping is inherently complex, since the
epigenome varies with age, diﬀers between tissues, is altered
by environmental factors, and shows aberrations in disease.
In an era of synthetic genomics and personalized medicine,
mapping of the epigenome at diﬀerent ages, in diﬀerent
tissue types and disease states should shed light on novel
biological functions and phenotypic diﬀerences of hetero-
geneous prostate cancer. The ability to detect and quantify
DNA methylation eﬃciently and accurately is important
for prostate cancer diagnosis. High resolution analysis of
individual CpG sites involves the chemical modiﬁcation
of DNA by bisulﬁte treatment, where sodium bisulﬁte
deaminates cytosine into uracil, whereasmethylated cytosine
is resistant to this conversion. Measurement of methylation
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PCR [82, 148], base-speciﬁc cleavage and mass spectrometry
[24, 149], Pyrosequencing [150], combined with bisulﬁte
restriction analysis (COBRA) [151] or methylation-sensitive
single nucleotide primer extension (Mu-SNuPE). The limi-
tation of these methods is the cost and scalability.
To comprehensively characterize the molecular eﬀects of
DNA methyltransferase inhibitors, high-resolution methods
need to be developed to analyze genome-wide methylation
patterns. These methods can also be used to develop and
reﬁne epigenetic therapies for cancer. If such methods can be
established, they will allow direct comparison of the biologic
eﬀectiveness of demethylation agents, as well as the opti-
mization of schedules and the rational designs of combined
treatments with DNA methylation inhibitors and other anti-
cancer drugs. Genome-wide approaches to analyze methyla-
tion involve comparative microarray hybridization following
fractionation of the genome, based upon methyl-cytosine-
speciﬁc antibodies and protein complexes or methylation-
speciﬁc enzymes with sites in CpG-rich regions [152–154].
The sensitivity of the enzymatic approach is limited by the
sequence context of the digestion site and by the number
of sites available. Bisulﬁte sequencing represents the most
comprehensive, high-resolution method for determining
DNA methylation states. Accurate quantiﬁcation of variable
methylationfrequenciesrequireshighsamplingofindividual
molecules. High-throughput, single-molecule sequencing
instruments have facilitated the genome-wide application of
this approach. However, these approaches are cost ineﬀective
and currently are impractical for routine application in com-
plex genomes with many epigenomic states. Recent strate-
gies for addressing methylation in large genomes include
enzyme directed reduced genomic representation followed
by parallel sequencing [155, 156] and bisulﬁte capture
technology, which combines bisulﬁte conversion with hybrid
selection techniques and deep sequencing [157]. Bisulﬁte
capture directs focus to speciﬁed CpG regions in a highly
parallelized process designed to selectively enhance sequence
information content by deeper sampling of targeted bases. In
addition, most of these techniques are highly labor intensive
and cannot be automated. Nanotechnology platforms based
on nanopore or nanowire-transition based ultra sensitive
detection of the methylated DNA show promise for routine
clinical diagnostics in the future [158, 159].
7. EpigeneticTherapy
Epigenetic changes are reversible, raising the possibility of
epigenetic therapy, which has led to the development of
epigenetic anticancer drugs such as demethylation agents
and histone deacetylation inhibitors (HDAC-I). Many genes
encoding enzymes, drug transporters, transcription factors,
cell cycle regulators, and nuclear receptors are under epige-
netic control. Thus, pharmacoepigenetics oﬀers a potential
mechanism for monitoring individual responses to treat-
ment that cannot be accounted for solely on the basis of
genetic polymorphisms. Ongoing studies to identify genes
that are diﬀerentially expressed in cancer cells versus normal
cells are providing valuable information about molecular
targets for epigenetic therapy [160]. Some drugs that inhibit
DNA methyltransferases have been shown to reactivate
silenced genes and induce diﬀerentiation or apoptosis of
malignant cells.
Two inhibitors of DNA methyltransferases, 5 -
azacytidine (Vidaza), and its derivative 5-aza-2 -
deoxycytidine (decitabine) have already been approved by
t h eF D Aa se ﬀective drugs for treatment of myelodysplastic
syndromes [161]. 5 -Azacytidine is a nucleoside inhibitor
that is incorporated into DNA. DNA methyltransferase
methylate both cytosine residues and 5 -azacytosine residues
in the DNA. However, 5 -azacytosine prevents the resolution
of a covalent reactive intermediate [162]. This leads to the
DNA methyltransferase being trapped and inactivated in the
form of a covalent protein-DNA adduct, which results in
depletion of cellular DNA methyltransferase. 5-Azacytidine
is a ribose nucleoside and thus must be chemically
modiﬁed to a deoxyribonucleotide triphosphatase to be
incorporated into DNA. Before 5-azacytidine is converted
into deoxyribonucleoside triphosphate, a portion of it is
incorporated into RNA, which aﬀects a variety of cellular
processes independent of demethylation [162]. Decitabine,
the deoxyribose analogue of 5-azacytidine, exhibits more
speciﬁcity with greater inhibition of DNA methylation
and less toxicity than 5-azacytidine. However, it also has
substantial toxic eﬀects. Other drugs aﬀect the epigenome,
such as zebularine, which is more stable than 5-azacytidine
or decitabine cytidine analog. The demethylation activity of
zebularine may also be diﬃcult to separate from the toxic
eﬀects of DNA methyltransferase depletion that results from
covalent enzyme trapping [163].
Some nonnucleoside compounds also inhibit DNA
methylation. EGCG, the main polyphenol compound in
green tea, binds to and blocks the active site of DNMT1
[7]. However, degradation of EGCG generates a substantial
amount of hydrogen peroxide [164] that might contribute
cytotoxic activity. RG108, a small-molecule inhibitor directly
and speciﬁcally inhibits DNMT1 with low toxicity [165].
Oligonucleotides, including hairpin-loops of DNA and a
speciﬁc antisense oligonucleotide, MG98, represent another
class of DNA methyltransferase inhibitors. Hairpin-loops of
DNA, which are competitive substrates for DNA methyl-
transferases, are able to induce a weak expression of the
t u m o rs u p p r e s s o rg e n ep16 [166]. MG98 has exhibited
antitumor activity in preclinical trials and is currently being
tested in a phase II clinical trials. Psammaplins, a natural
product derived from the sea sponge pseudoceratina pur-
purea, inhibits DNMTs as well as histone deacetylases. SAHA
(suberoylanilide hydroxamic acid), an HDAC inhibitor,
has been approved by FDA for the treatment of T cell
cutaneous lymphoma. Several other HDAC inhibitors such
as depsipeptide and phenylbutyrate are currently in clinical
trials.InadditiontoDNAmethylationandHDACinhibitors,
histone arginine methyltransferases are emerging anticancer
targets, due to their role as coregulators of the androgen
receptor [167]. The histone methyltransferase inhibitor
DZNep induces apoptosis in cancer cells by selectively
targeting polycomb repressive complex 2 (PRC2) proteins,
which are generally overexpressed in cancer cells [168]. Also,8 Obstetrics and Gynecology International
combinations of DNA methylation and HDAC inhibitors
with classic chemotherapeutics have shown promise in solid
malignancies [169]. However, many studies suggest that
demethylation of speciﬁc genes need not always result in
reexpression [170, 171]. For example, demethylation of the
MAGE gene appears to lead to reexpression only when the
appropriate tissue-speciﬁc transcription factors are present
[172]. Thus, various factors including nonspeciﬁc global
hypomethylation and cytotoxic side eﬀects may contribute
to the complex alterations observed after epigenetic drug
treatments. The characterization of these eﬀects and devel-
opment of compounds that speciﬁcally reverse abnormal
DNA methylation patterns or epimutations will be required
for future cancer therapies. The broad use of decitabine in
cell culture experiments indicates that demethylation of the
tumor suppressor genes can occur at drug concentrations
lower than those required for cytotoxicity [173]. Treatment
schedules have to be modiﬁed to include multiple courses
of treatment to sustain demethylation and reduce drug
concentrations to decrease the severity of side eﬀects.
As DNA methylation and hypoacetylation have been
shown to contribute to silencing of chemotherapeutic
sensitive genes; reversal of these modiﬁcations to allow
reexpression of such genes is one possible second-line
treatment for prostate cancer. These treatments would then
be combined with conventional ﬁrst-line therapies to elicit
tumor regression. In a comprehensive study of several
tumor cell lines, 5-aza-deoxycytidine allowed for apoptotic
resensitization to a variety of agents, including doxorubicin
and cisplatin [174]. Demethylating agents, HDAC inhibitors
or combinations may allow for reexpression of silenced
tumor suppressors such as hMLH1 and RASSF1A. A loss of
hMLH1 and RASSF1A contributes to multidrug resistance
phenotype [175]. Epigenetic reexpressions of these genes
might allow for resensitization of tumors to the conven-
tional ﬁrst-line therapies. Other epigenetic targets could be
methyl binding proteins and miRNAs, which play a role
in tumor suppressor silencing [176]. Resistance of human
tumor xenografts to treatment with cisplatin, carboplatin,
temozolomide and epirubicin was decreased by adding
nontoxic doses of decitabine [177, 178]. Importantly the
timing of drug administration appears to be associated with
therapeutic responses. Structurally designed small molecule
inhibitors may enhance speciﬁcity in epigenetic targeting,
avoiding the potential detriments of global demethylation
and hyperacetylation.
8. Conclusion
Chromatin structure and packaging of the genome is
important for regulating the cellular homeostasis. ROS-
induced oxidative stress is involved in the multistage process
of prostate cancer progression. In particular, there is a
growing interest in the involvement of oxidative stress in
the epigenetic regulation of gene expression and speciﬁcally
in controlling DNA methylation. Agents that prevent the
production and chronic accumulation of ROS might play
an important role in the treatment of prostate cancer.
Epigenetic alterations are clearly involved in prostate cancer
initiation and progression. Hypermethylated genes can be
used to detect early stage of prostate cancer. In addition to
the use of epigenetic alterations as a means of screening,
epigenetic alteration may help clinicians to predict the
risk of recurrence and drug resistance. A combinatorial
approachofepigenetictherapywithantioxidantagentsalong
with standard radiotherapy and targeted anticancer therapy
may help in sensitization of tumors which are resistant to
current approaches of treatment. Finally, a link between the
biomarkers and therapy may have positive impact on health
care.
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